E/C/F/TAF (Low Dose)

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Acquired Immune Deficiency Syndrome (AIDS)HIV InfectionsHIV-1-infection

Phase 2

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

CompletedNCT01854775

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2013-05-06End: 2025-06-18Updated: 2026-01-09

Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

RecruitingNCT06337032

Gilead SciencesHIV-1-infection

Start: 2024-08-27End: 2034-03-01Target: 350Updated: 2026-03-16

Related Papers

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy

Journal of the Pediatric Infectious Diseases Society2025-07-01

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg

Journal of the International AIDS Society2025-01-30

Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.

2017-06-2924 citations

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

2016-10-1733 citations